Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis
NCT ID: NCT02338427
Last Updated: 2018-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
140 participants
INTERVENTIONAL
2016-05-31
2018-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The application of conventional techniques immunolabeling of amylose does not allow the comprehensive characterization of amylose forms, due to failures of the technic, the false positivity of some results, or lack of frozen tissue available for typing light chain (lambda, kappa).
In this study, the main objective is the comparison of two capacity of amylose characterisation: immunohistochemistry and proteomics analysis.
The purpose of this study is to validate the superiority of proteomic analysis by demonstrating the improvement of the precision, the reduction of technical failure, as well as the correction of erroneous diagnosis, authorizing a more adapted therapeutic management.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
proteomic
Immunohistochemistry
Proteomic analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Immunohistochemistry
Proteomic analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Amylose diagnosis establish by tissue sample, after "Rouge Congo" coloration
* All patient with amylose identified by the two laboratory of anatomopathology
* Sample necessary for realized proteomic analysis
* No opposition at the participation of the study
* Patient sign an informed consent for biology collection
Exclusion Criteria
* Patient trust, guardianship, under legal protection measure, deprived of freedom
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Departemental Vendee
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hervé MAISONNEUVE, PH
Role: STUDY_DIRECTOR
Centre Hospitalier Départementel Vendée
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Departemental Vendee
La Roche-sur-Yon, , France
CHU de Nantes
Nantes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHD 063-14
Identifier Type: -
Identifier Source: org_study_id